The National Amyotrophic Lateral Sclerosis (ALS) Registry patient guide

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

The National Amyotrophic Lateral Sclerosis (ALS) Registry patient guide

Published Date:

6/13/12

Language:

English

[PDF-3.05 MB]

Details:

Corporate Authors:

United States. Agency for Toxic Substances and Disease Registry.

Keywords:

[+]

Description:

The National ALS Registry is a program to collect, manage, and analyze data about people with ALS. It is important to include as many people with the disease as pos- sible to get the most accurate information.

Because learning more about ALS is an important step in the battle to defeat it, the Agency for Toxic Substances and Disease Registry (ATSDR) has developed a national registry to gather information from people who are living with ALS. This information can help doctors and scientists learn more as they work toward a cure.

CS216408-A

Publication date from document properties.

Document Type:

Pamphlet (or booklet)

Collection(s):

Stephen B. Thacker CDC Library collection

Supporting Files:

No Additional Files

No Related Documents.

You May Also Like:

A National assessment of amyotrophic lateral sclerosis and other chronic neurologic conditions state surveillance programs : a report for the Agency for Toxic Substances and Disease Registry (ATSDR)

Personal Author:

Chao, Ed; Simms, Erin;

Corporate Author:

Council of State and Territorial Epidemiologists.. United States. Agency for Toxic Substances and Disease Registry..

Published:

June 6, 2009

Description:

On October 8, 2008, the President signed the ALS Registry Act (Public Law No. 110- 373) into law. It authorizes the Centers for Disease Control and Prevention (CDC) to establish a national amyotrophic lateral sclerosis (ALS) patient registry to ident...

File Type:

[PDF - 110.06 KB]
A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013

Personal Author:

Horton, D. Kevin; Graham, Shannon; Punjani, Reshma; Wilt, Grete; Kaye, Wendy; Maginnis, Kimberly; Webb, Lauren; Richman, Judy; Bedlack, Richard; Tessaro, Edward; Mehta, Paul;

Published:

Dec 20 2017

Source:

Amyotroph Lateral Scler Frontotemporal Degener. 19(1-2):126-133.

Description:

Background : Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that typically results in death within 2–5 years of initial symptom onset. Multidisciplinary ALS clinics (MDCs) have been established to provide specialty care to peop...

File Type:

[PDF - 85.48 KB]
Evaluating the completeness of the national ALS registry, United States

Personal Author:

KAYE, WENDY E.; WAGNER, LAURIE; WU, RUOMING; MEHTA, PAUL;

Published:

Oct 11 2017

Source:

Amyotroph Lateral Scler Frontotemporal Degener. 19(1-2):112-117.

Description:

Our objective was to evaluate the completeness of the United States National ALS Registry (Registry). We compared persons with ALS who were passively identified by the Registry with those actively identified in the State and Metropolitan Area ALS Sur...

File Type:

[PDF - 78.69 KB]
Summary report : Amyotrophic Lateral Sclerosis and Multiple Sclerosis Surveillance annual meeting : February 26, 2008 : Issues related to developing a national surveillance system and registries for amyotrophic lateral sclerosis and multiple sclerosis

Corporate Author:

United States. Agency for Toxic Substances and Disease Registry.

Published:

2008

Description:

This document has not been revised or edited to conform to agency standards. The findings and conclusions in this report are those of the meeting presenters and attendees and do not necessarily represent the views of the Agency for Toxic Substances a...

File Type:

[PDF - 678.96 KB]
CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions

Personal Author:

Mehta, Paul; Horton, D. Kevin; Kasarskis, Edward J.; Tessaro, Ed; Eisenberg, M. Shira; Laird, Susan; Iskander, John;

Published:

Dec 22 2017

Source:

MMWR Morb Mortal Wkly Rep. 66(50):1379-1382.

Description:

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a rapidly progressive fatal neurologic disease. Currently, there is no cure for ALS and the available treatments only extend life by an average of a few months. The major...

File Type:

[PDF - 107.88 KB]